BioTek reMEDys Revenue and Competitors
Estimated Revenue & Valuation
- BioTek reMEDys's estimated annual revenue is currently $29.9M per year.
- BioTek reMEDys's estimated revenue per employee is $201,000
Employee Data
- BioTek reMEDys has 149 Employees.
- BioTek reMEDys grew their employee count by 13% last year.
BioTek reMEDys's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Strategic Healthcare Partnerships | Reveal Email/Phone |
3 | Director Operations | Reveal Email/Phone |
4 | Senior Director Compliance, Contracts & Legal Operations | Reveal Email/Phone |
5 | Director Pharmacy at Biotek Remedys South | Reveal Email/Phone |
6 | Director Enterprise Strategy | Reveal Email/Phone |
7 | Director Quality Management and Clinical Operations | Reveal Email/Phone |
8 | Director Pharmacy at BioTek reMEDys West | Reveal Email/Phone |
9 | IT Department Manager | Reveal Email/Phone |
10 | Pharmacy Manager | Reveal Email/Phone |
BioTek reMEDys Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $44.4M | 221 | 31% | N/A | N/A |
#2 | $10.3M | 51 | -27% | N/A | N/A |
#3 | $83.2M | 414 | 6% | N/A | N/A |
#4 | $59.9M | 298 | -9% | N/A | N/A |
#5 | $9.4M | 47 | 42% | N/A | N/A |
#6 | $136.3M | 678 | -8% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $0.7M | 7 | 0% | N/A | N/A |
#9 | $3M | 15 | 50% | N/A | N/A |
#10 | $9.6M | 48 | 7% | N/A | N/A |
What Is BioTek reMEDys?
We are a national Specialty Pharmacy company providing medications and support services to patients, prescribers, payers and manufacturers.
keywords:N/AN/A
Total Funding
149
Number of Employees
$29.9M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $26.6M | 151 | 36% | N/A |
#2 | $35.1M | 152 | -1% | N/A |
#3 | $26.2M | 164 | 27% | N/A |
#4 | $63.5M | 175 | -1% | N/A |
#5 | $53.8M | 181 | -11% | N/A |